ACM Research (ACMR) CEO gains 545,400 performance-based options as value target hit
Rhea-AI Filing Summary
ACM Research CEO David H. Wang reported the vesting of performance-based stock options tied to the company’s market value. On February 4, 2026, 545,400 stock options with a $7.36 exercise price became exercisable, bringing his total outstanding options to 1,636,197 shares of Class A common stock.
The options were originally granted on March 20, 2020 and vest in three tranches when ACM Research’s market capitalization increases by $1 billion, $2 billion, and $3 billion from $553,383,586 at grant. The latest vesting was triggered when market capitalization first reached or exceeded $3,553,383,586. The filing also lists indirect holdings of Class A common stock through family members and family trusts.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Wang David H
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 545,400 | $0.00 | $0.00 |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
| holding | Class A Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 1,636,197 shares (Direct);
Class A Common Stock — 100,002 shares (Indirect, By Jing Chen, wife of David H. Wang);
Class A Common Stock — 45,837 shares (Indirect, By Sophia Wang, daughter of David H. Wang);
Class A Common Stock — 180,000 shares (Indirect, By David Hui Wang and Jing Chen Family Irrevocable Trust for Wang Children);
Class A Common Stock — 620,001 shares (Indirect, By Wang-Chen Family Living Trust)
Footnotes (2)
- F1. On March 20, 2020, the reporting person was granted options to purchase an aggregate of 1,636,197 shares of the Issuer's Class A common stock, based on the satisfaction of certain performance criteria. In general, one-third of the shares subject to the options vest and become exercisable upon an increase in the Issuer's market capitalization (calculated as described in footnote 2) of $1 billion, $2 billion and $3 billion, respectively, from the market capitalization of $553,383,586 on the date of grant. 545,400 shares vested and became exercisable on February 4, 2026, which was the first trading day as of which the Issuer's market capitalization equaled or exceeded $3,553,383,586.
- F2. For purposes of the options, the market capitalization as of a specified trading day is calculated by multiplying (a) the average of the daily volume-weighted average price per share of the Issuer's Class A common stock for each of the trading days occurring during the thirty calendar day period ending on that specified trading day by (b) the total number of issued and outstanding shares of the Issuer's Class A and Class B common stock as of 11:59 p.m. (Eastern time) on such specified trading day.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did ACMR CEO David H. Wang report on February 4, 2026?
David H. Wang reported the vesting of 545,400 performance-based stock options on February 4, 2026. These options became exercisable when ACM Research’s market capitalization reached a preset threshold, increasing his outstanding option holdings to 1,636,197 shares of Class A common stock.
How many ACMR stock options does David H. Wang hold after this Form 4 filing?
After the reported vesting, David H. Wang holds 1,636,197 stock options for ACM Research Class A common stock. These options stem from a March 20, 2020 grant that vests in tranches based on the company achieving specified market capitalization increases over the grant-date level.
What performance conditions triggered David H. Wang’s ACMR option vesting?
The vesting depends on ACM Research’s market capitalization rising by $1 billion, $2 billion, and $3 billion from $553,383,586 at grant. The 545,400 options vested when market capitalization first equaled or exceeded $3,553,383,586, satisfying the highest performance threshold under the grant’s terms.
When were David H. Wang’s ACMR performance stock options originally granted?
The options were granted on March 20, 2020 as a performance-based award covering 1,636,197 shares. Vesting occurs in three tranches as ACM Research’s market capitalization surpasses specified billion-dollar increases from the grant-date market capitalization of $553,383,586.
What is the exercise price and expiration date of David H. Wang’s ACMR stock options?
The reported stock options have a $7.36 exercise price per share and an expiration date of March 19, 2030. They were structured as performance-based options, with vesting tied to ACM Research’s market capitalization milestones achieved after the original 2020 grant date.